Armin Giese, M.D.

Before joining MODAG as Chief Scientific Officer (CSO), Dr. Giese was Acting Head at the Center for Neuropathology and Prion Research (LMU Munich) and Acting Head of the German Reference Center for Neurodegenerative Diseases (DGNN). He has authored more than 200 papers (with over 25,000 citations) with a focus on protein aggregation and toxic oligomers in neurodegenerative disease. He developed single‑particle spectroscopy methods for quantitative oligomer analysis and high‑throughput screening of aggregation inhibitors. This SIFT‑based approach enabled the identification of small‑molecule oligomer modulators with excellent pharmaceutical properties and strong in‑vivo efficacy, including emrusolmin (anle138b), now in a Phase 2 trial in multiple system atrophy (MSA). Dr. Giese also develops diagnostics for pathological alpha‑synuclein, including seed amplification assays (SAA) and PET tracers, to support patient stratification and drug development. He co‑founded MODAG GmbH in 2013. He continues to lead MODAG’s research programs spanning therapeutics, biomarkers and imaging.